Align Technology's New ITero Scanner Updates To Boost Uptake
Zacks Investment Research | Nov 26, 2018 09:02PM ET
Align Technology, Inc. (NASDAQ:ALGN) recently announced several updates to its iTero Element family of Intraoral scanner (iTero Element, Element 2 and Element Flex), expanding its usage in restorative and dental practice workflow.
The company also informed about its plans to initiate the 1.7 iTero scanner software upgrade launch starting from late November. With this, users will be able to access new features which enhance scan quality and provide better patient data protection.
With connectivity available only in North America, iTero Intraoral scanner has been integrated with Dentrix patient management platform resulting in simplified workflow and enhanced efficiency.
Market Potential
Per a Research And Markets report, the global 3D dental scanner market is expected to see a CAGR of 10.2% in the 2017-2021 period. The latest developments will help Align Technology cash in on the opportunities.
iTero Portfolio in Focus
Of late, Align Technology has been focusing on expanding work flow options of iTero scanners. The company has been gaining significantly from shipments of the iTero Element intraoral scanner to China. Moreover, the company has begun manufacturing the iTero Element intraoral scanner in China post-receipt of Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration (CFDA).
The company is also gaining from the adoption of the iTero platform by dental service organizations or DSO partners.
Align Technology also expanded its iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States and majority of European countries, including France, Germany, Italy, Spain, and the United Kingdom.
Align Technology received encouraging response for its Invisalign Go product with an improved user-interface in iTero digital chairside experience and increased flexibility for treating variety of mild to moderate cases. Notably, the product was made commercially available in North America, Australia, New Zealand, and certain markets in Europe starting Jul 1, 2018.
Share Price Movement
Over the past year, Align Technology’s share price has underperformed its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.